US Plasma Fractionation Market Size was valued at USD 12.8 Billion in 2022. The US Plasma Fractionation market industry is projected to grow from USD13.76 billion in 2023 to USD 24.54 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.50% during the forecast period (2023 - 2032). Rising consumer awareness, changing eating habits, and the growing significance of US Plasma Fractionation for better health are the main market drivers anticipated to propel the US Plasma Fractionation market in the United States.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
A prominent trend in the US Plasma Fractionation market is the escalating demand for plasma-derived therapies. Plasma fractionation involves separating and processing blood plasma to extract specific proteins, which are then used to produce various therapeutic products. The rising prevalence of chronic diseases, autoimmune disorders, and genetic deficiencies has spurred the demand for plasma-derived therapies such as immunoglobulins, clotting factors, and albumin. These therapeutic products are crucial in treating conditions like haemophilia, immune deficiencies, and neurological disorders. The expanding application of plasma-derived therapies and their efficacy in managing a spectrum of medical conditions contribute to the sustained growth and innovation within the plasma fractionation market. This factor drives market CAGR.
Furthermore, another significant trend involves continuous technological advancements and an increased focus on quality assurance in plasma fractionation processes. Innovations in separation technologies, purification methods, and virus inactivation techniques are enhancing the efficiency and safety of plasma fractionation. The industry is investing in advanced technologies to ensure the production of high-quality plasma-derived products while adhering to stringent regulatory standards. Quality assurance measures, including virus screening and removal processes, are critical in safeguarding the safety of plasma-derived therapies. As the demand for plasma-derived products rises, the market trend emphasizes a commitment to technological advancements and rigorous quality control measures to meet the growing healthcare needs and ensure the safety and efficacy of plasma fractionation products in the US healthcare landscape.Thus driving the US Plasma Fractionation market revenue.
Based on Applications, the US Plasma Fractionation market segmentation includes Immunology, Hematology, and Others. Immunology is the dominant category in the US Plasma Fractionation market, primarily fueled by the increasing demand for immunoglobulins. Immunoglobulins, also known as antibodies, are crucial components derived from plasma and play a vital role in treating various autoimmune disorders, primary immunodeficiency diseases, and neurological conditions. The versatile applications of immunoglobulins in providing passive immunity and modulating the immune system contribute to their dominance in the plasma fractionation market. Additionally, haematology is the fastest-growing category in the US plasma filtration market, propelled by advancements in clotting factor therapies. Plasma fractionation is crucial in extracting clotting factors for treating haemophilia, von Willebrand disease, and other bleeding disorders. Ongoing innovations in clotting factor concentrates, improved purification techniques, and personalized treatment approaches drive the rapid growth in haematology applications.
Figure1:U.S. Plasma Fractionation Market, by Applications, 2022 & 2032(USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Based on Product Types, the US Plasma Fractionation market segmentation includes Albumin, Immune Globulin, Coagulation Factor, and Others. Immune Globulin (I.G.) products emerge as the dominant category in the US Plasma Fractionation market, owing to their wide therapeutic applications and increasing demand. I.G. products derived from plasma are crucial in treating various autoimmune disorders, immunodeficiency conditions, and neurological disorders. The versatility of I.G. in providing passive immunity, modulating the immune system, and managing chronic conditions positions it as a cornerstone in the plasma fractionation market. Additionally, the fastest-growing category in the US plasma filtration market is coagulation factor products, driven by advancements in haematology and bleeding disorder treatments. Coagulation factors extracted through plasma fractionation are critical in treating conditions such as haemophilia and von Willebrand disease. Ongoing innovations in clotting factor concentrates, purification technologies, and personalized treatment approaches are propelling the rapid growth of Coagulation Factor products.
In the United States, the Plasma Fractionation market reflects a robust and dynamic landscape driven by the growing demand for plasma-derived therapies. Immunoglobulins, dominating the market, cater to diverse immunological disorders, showcasing the crucial role of plasma fractionation in treating autoimmune and immunodeficiency conditions. Concurrently, advancements in clotting factor therapies drive the rapid growth of haematology applications, meeting the evolving therapeutic needs of patients with bleeding disorders. The market's focus on Immune Globulin products underscores their versatility, while the surge in Coagulation Factor products highlights the commitment to advancing haematology treatments. With increasing awareness, technological innovations, and a broad spectrum of therapeutic applications, the US Plasma Fractionation market stands at the forefront of providing essential and tailored therapies for various medical conditions.
Prominent industry participants are making significant investments in R&D to broaden their product offerings, contributing to the further expansion of the US Plasma Fractionation market. In addition, market participants are engaging in a range of strategic endeavors aimed at broadening their market reach. Notable events in this regard include the introduction of new products, contractual agreements, mergers and acquisitions, increased investment levels, and cooperation with other entities. In order to grow and thrive in a more competitive and rising market environment, the US Plasma Fractionation business needs to provide affordable products.
Major players in theUS Plasma Fractionationmarket are attempting to increase market demand by investing in research and development operations, including Takeda, CSL, rifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO.
April 2023:CSL (Australia) received Food and Drug Administration (FDA) approval for the 50mL/10gm prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid for patients suffering from P.I. and CIPD.
March 2022:Grifols (Spain) received European approvals for XEMBIFY, a 20% subcutaneous immunoglobulin (SCIG).
| Report Attribute/Metric | Details |
| Market Size2022 | USD 12.8Billion |
| Market Size 2023 | USD 13.7Billion |
| Market Size2032 | USD 24.5Billion |
| Compound Annual Growth Rate (CAGR) | 7.50%(2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Distribution Channel, and Region |
| Countries Covered | The U.S. |
| Key Companies Profiled | Takeda, CSL, rifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO. |
| Key Market Opportunities | Rising consumer awareness Changing eating habits |
| Key Market Dynamics | Growing significance of U.S. Plasma Fractionation for better health |
US Plasma Fractionation Market Highlights:
Frequently Asked Questions (FAQ) :
The U.S. Plasma Fractionation market size was valued at USD 12.8 Billion in 2022.
The market is projected to grow at a CAGR of 7.50% during the forecast period, 2023-2032.
The key players in the market are Takeda, CSL, rifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO.
The Immunology category dominated the market in 2022.
The Immune Globulin category has the largest share of the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
